Chunxia Liu

Dr. Chunxia Liu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2019 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
CLChunxia Liu
Chunxia Liu
XYXiaojian Yao
Xiaojian Yao
MLMing Li
Ming Li
YXYaming Xi
Yaming Xi
LZLi Zhao
Li Zhao
Ubiquitin-specific peptidase 39 (USP39) is one member of the cysteine proteases of the USP family, which represents the largest group of DeUbiquitinases with more than 50 members in humans. The roles of USP39 in human cancer have been widely investigated. However, the roles of USP39 in human leukemia and the underlying mechanism remain unknown. Here we reported the function of USP39 in human leukemia. We observed that the expression of USP39 was up-regulated in human leukemia cells and the high expression of USP39 was correlated with poor survival of the patients with leukemia. Lentivirus-mediated knockdown of USP39 repressed the proliferation and colony formation of human leukemia cell lines HL-60 and Jurkat cells. Mechanism study showed that USP39 knockdown induced the arrest of cell cycle and apoptosis of leukemia cells. In addition, our microarray and bioinformatic analysis demonstrated that USP39 regulated diverse cellular signaling pathways that were involved in tumor biology, and several pivotal genes (IRF1, Caspase 8, and SP1) have been validated by quantitative real-time polymerase chain reaction. Knockdown or IRF1 partially restored the proliferation rate of leukemia cells with USP39 knockdown. Taken together, our findings implicate that USP39 promotes the development of human leukemia by regulating cell cycle, survival, and proliferation of the cells.

1 July 2018 in Medicine
Verified
Journal Article
Open access
CLChunxia Liu
Chunxia Liu
MLMing Li
Ming Li
XWXiaomei Wu
Xiaomei Wu
XYXiaojian Yao
Xiaojian Yao
LZLi Zhao
Li Zhao
We describe a novel case of half-brothers suffering from type 2 familial hemophagocytic lymphohistiocytosis (FHL). A 15-year-old Chinese child was admitted to the hematology department. PRF1 gene coding revealed that he was c.282C>A/p.N94K heterozygous and had a c.1349C>T/p.T450M heterozygous mutation. One year later, his younger halfbrother suffered from the same disease. PRF1 gene coding revealed that the younger brother was c.282C>A/p.T450M heterozygous with a c.1349C>T/p.T450M heterozygous mutation. His mother and grandfather were confirmed to have c.1349C>T/p.T450M heterozygous mutations in exon 3. Half-brothers were diagnosed for type 2 familial hemophagocytic lymphohistiocytosis To our knowledge, this is a possible FHL and the children's mother may be a pathogenic gene carrier. After being treated with the HLH-04 schedule, the symptoms of half-brothers were all improved. Therefore, once FHL is diagnosed, HSCT needs to be done early, even if no perfect match is found.

14 May 2026 in Cell Biology International
Verified
Journal Article
Closed access
HWHan Wang
Han Wang
JTJiaqi Tian
Jiaqi Tian
MZMing Zhang
Ming Zhang
LZLiyuan Zhang
Liyuan Zhang
CLChunxia Liu
Chunxia Liu
WJWenjuan Jia
Wenjuan Jia